Limits...
Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis.

Chen Y, Wu G, Zhang H, Xu H, Li H, Chen L, Yang Y, Hu P, Zhang D, Ren H, Hu H - Gastroenterol Res Pract (2015)

Bottom Line: We searched electronic databases up to July 31, 2013, to obtain relevant research reports that satisfied the inclusion criteria.The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

ABSTRACT
Background. Graft reinfection with hepatitis C (HCV) after liver transplantation is a significant problem in transplant hepatology. This meta-analysis was performed to compare the effectiveness and risk of adverse events of interferon-based therapy with no treatment after liver transplantation. Methods. We searched electronic databases up to July 31, 2013, to obtain relevant research reports that satisfied the inclusion criteria. Meta-analyses were done on randomized controlled trials (RCTs) and nonrandomized trials. Results. A meta-analysis was performed on 2 RCTs and 2 cohort studies comprising a total of 326 patients (171 of whom accepted interferon-based antiviral therapy). The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks. Patients in the antiviral group had higher sustained virological response (SVR) rates and lower mean alanine aminotransferase levels relative to controls at 48 weeks, but more total serious adverse events (AEs) than controls. Conclusions. Interferon-based treatment has some efficacy in the treatment of HCV graft reinfection following liver transplantation.

No MeSH data available.


Related in: MedlinePlus

Treatment with interferon-based antiviral therapy group and SVR rates. SVR: HCV-RNA in the serum by qualitative polymerase chain reaction measured at 24 weeks of follow-up after the end of treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4488578&req=5

fig3: Treatment with interferon-based antiviral therapy group and SVR rates. SVR: HCV-RNA in the serum by qualitative polymerase chain reaction measured at 24 weeks of follow-up after the end of treatment.

Mentions: Four of the studies revealed that the treatment group had higher SVR rates than the controls (RR = 24.34, 95% CI: 5.88–100.74, P < 0.0001, Figure 3) [11, 13–15].


Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis.

Chen Y, Wu G, Zhang H, Xu H, Li H, Chen L, Yang Y, Hu P, Zhang D, Ren H, Hu H - Gastroenterol Res Pract (2015)

Treatment with interferon-based antiviral therapy group and SVR rates. SVR: HCV-RNA in the serum by qualitative polymerase chain reaction measured at 24 weeks of follow-up after the end of treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4488578&req=5

fig3: Treatment with interferon-based antiviral therapy group and SVR rates. SVR: HCV-RNA in the serum by qualitative polymerase chain reaction measured at 24 weeks of follow-up after the end of treatment.
Mentions: Four of the studies revealed that the treatment group had higher SVR rates than the controls (RR = 24.34, 95% CI: 5.88–100.74, P < 0.0001, Figure 3) [11, 13–15].

Bottom Line: We searched electronic databases up to July 31, 2013, to obtain relevant research reports that satisfied the inclusion criteria.The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

ABSTRACT
Background. Graft reinfection with hepatitis C (HCV) after liver transplantation is a significant problem in transplant hepatology. This meta-analysis was performed to compare the effectiveness and risk of adverse events of interferon-based therapy with no treatment after liver transplantation. Methods. We searched electronic databases up to July 31, 2013, to obtain relevant research reports that satisfied the inclusion criteria. Meta-analyses were done on randomized controlled trials (RCTs) and nonrandomized trials. Results. A meta-analysis was performed on 2 RCTs and 2 cohort studies comprising a total of 326 patients (171 of whom accepted interferon-based antiviral therapy). The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks. Patients in the antiviral group had higher sustained virological response (SVR) rates and lower mean alanine aminotransferase levels relative to controls at 48 weeks, but more total serious adverse events (AEs) than controls. Conclusions. Interferon-based treatment has some efficacy in the treatment of HCV graft reinfection following liver transplantation.

No MeSH data available.


Related in: MedlinePlus